Qiagen Stock Soars in November on Acquisition Speculation, Helping Push GenomeWeb Index Higher

NEW YORK – The GenomeWeb Index rose more than 6 percent in November, as several stock saw gains in the double digits.

The index outperformed the Dow Jones Industrial Average and the Nasdaq — which gained nearly 4 percent and nearly 5 percent, respectively — but underperformed the Nasdaq Biotechnology Index, which gained more than 11 percent. Individual stock performance in the GenomeWeb Index was mostly positive as 24 of the 31 stocks saw gains and seven saw losses.